VR-CAR / Boryung Group, ViGenCell - LARVOL DELTA

Optimization of velocity receptor transduction in CAR T cells. (PubMed, bioRxiv) - "We also observed a log-linear relationship between viral dose and transduction efficiency for a subset of VRs previously tested in various mouse models of human cancer, with VR5αIL8 and VR5αTNFα VRs consistently outperforming VR5αIL5 and V5 (full length native IL5 receptor). Overall, these findings establish an optimized and reproducible framework that offers valuable guidance for the future development and functional study of VR-CAR T cells in cellular therapies for solid tumors."

Journal • Oncology • Solid Tumor • CXCL8 • IL5 • TNFA

Vigencell, ICBMT, 3 research results abstracts accepted including oral presentations [Google translation] (Pharm News) - "Vigencell...announced on the 20th that it will hold one oral presentation and two poster presentations along with abstract adoption at the International Conference of the Korean Society for Blood and Marrow Transplantation...to be held in September...Vigencell will present that the administration of VT-Tri derived from donors after hematopoietic stem cell transplantation (HSCT) is safe and can be a good treatment option for patients with relapsed or refractory AML...first poster presentation will present the results of a study...The study compared the efficacy of CAR-T cells with CD30-derived signaling domains with conventional CD28, 4-1BB CAR-T cells in an animal model of blood cancer, and CAR-T cells with CD30-derived signaling domains showed better performance in survival rate and body weight maintenance than conventional CAR-T cells in animal experiments....it was confirmed that γδ T cells stimulated with aAPCs showed long-term proliferation and enhanced cell activation..."

Clinical data • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Oncology